• cheap windows server 2003 oem buy adobe lightroom student purchase microsoft office home and student best price paperport 12 cost of nero sdk cheap access 2003 buy cheap windows 7 online buy outlook 2010 upgrade buy visio 2003 uk price of microsoft windows xp home edition buy microsoft access 2000 windows seven student discount buy corel designer 9 buying windows 7 ultimate activation key cost of office 2008
  • buy acrobat 8 pro buy windows 7 pro buying filemaker server cheap autodesk 3ds max cheap office 2003 upgrade buy 2003 office professional cheap adobe photoshop cs4 to buy price of adobe flash player buying word 2007 online buy acronis 2010 adobe photoshop cs5 cheapest price buy windows xp 2010 buy autocad civil 3d 2009 purchase windows xp professional 64 bit buy autodesk inventor 2011

    Cancer Prevention Research

    Mon, Nov 25, 2013

    Oral Cancer News

     

    Clinical and biochemical studies support smokeless tobacco’s carcinogenic potential in the human oral cavity

     
    Source: American Association of Cancer Research
    Published: November 9, 2013
    By: Susan R. Mallery, Meng Tong, Gregory C. Michaels, Amber R. Kiyani, and Stephen S. Hecht

     

    Abstract

    In 2007, International Agency for Cancer Research presented compelling evidence that linked smokeless tobacco use to the development of human oral cancer. While these findings imply vigorous local carcinogen metabolism, little is known regarding levels and distribution of Phase I, II and drug egress enzymes in human oral mucosa. In the study presented here, we integrated clinical data, imaging and histopathologic analyses of an oral squamous cell carcinoma that arose at the site of smokeless tobacco quid placement in a patient. Immunoblot and immunohistochemical (IHC) analyses were employed to identify tumor and normal human oral mucosal smokeless tobacco-associated metabolic activation and detoxification enzymes. Human oral epithelium contains every known Phase I enzyme associated with nitrosamine oxidative bioactivation with ~2 fold inter-donor differences in protein levels. Previous studies have confirmed ~3.5 fold inter-donor variations in intraepithelial Phase II enzymes. Unlike the superficially located enzymes in non-replicating esophageal surface epithelium, IHC studies confirmed oral mucosal nitrosamine metabolizing enzymes reside in the basilar and suprabasilar region which notably is the site of ongoing keratinocyte DNA replication. Clearly, variations in product composition, nitrosamine metabolism and exposure duration will modulate clinical outcomes. The data presented here form a coherent picture consistent with the abundant experimental data that links tobacco-specific nitrosamines to human oral cancer.

     

    * This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

     

    Print Friendly
    Be Sociable, Share!
    , , ,

    Leave a Reply

    You must be logged in to post a comment.